Protamine Sulphate (Heparin Reversal)
Brand names: Protamine Sulphate 1%
Protamine sulphate is an intravenous antidote used to neutralise the anticoagulant effect of heparin, most often to reverse unfractionated heparin after cardiopulmonary bypass or other procedures.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Protamine is a strongly basic protein that binds electrostatically to acidic heparin to form an inactive stable complex, abolishing heparin's antithrombin-mediated anticoagulant activity; it only partially reverses low-molecular-weight heparins.
Prescribing in practice
- Inject slowly because rapid administration can cause severe hypotension, bradycardia, anaphylactoid reactions and pulmonary hypertension; have resuscitation facilities available.
- Patients exposed to protamine-containing insulins, those with fish allergy and men who are infertile or have had a vasectomy are at higher risk of hypersensitivity.
- Excessive protamine has its own anticoagulant effect, and rebound anticoagulation (heparin rebound) can occur after cardiac surgery; titrate the dose to the heparin to be neutralised.
Monitoring
Monitor blood pressure, heart rate and coagulation parameters such as the activated clotting time or APTT during and after administration to confirm reversal and detect rebound.
Counselling the patient
- Inform the team if you have a fish allergy, take a protamine-containing insulin or have had a vasectomy.
- Report any breathlessness, flushing or feeling faint during the injection.
Evidence & guidelines
Protamine reversal of heparin is standard practice in cardiac surgery and established prescribing references, with MHRA-recognised risks of serious cardiovascular and hypersensitivity reactions on rapid administration.
Reference: Cardiothoracic Anaesthesia Society Guidelines; AAGBI Guidelines; SPC Protamine Sulphate 1%; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- ASA Physical Status Classification · Pre-operative Risk
- Train-of-Four (TOF) Neuromuscular Monitoring · Neuromuscular Blockade
- Revised Cardiac Risk Index (RCRI / Lee Index) · Perioperative Risk
- Vasoactive-Inotropic Score (VIS) · Inotropic Support
- Cardiac Output (Fick Method) · Haemodynamics
- Revised Cardiac Risk Index (RCRI) · Pre-operative Risk
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines